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Abstract
The humoral immune response plays a critical role in controlling infection, and the rapid adaptation to a broad range of
pathogens depends on a highly diverse antibody repertoire. The advent of high-throughput sequencing technologies in the
past decade has enabled insights into this immense diversity. However, not only the variable, but also the constant region
of antibodies determines their in vivo activity. Antibody isotypes differ in effector functions and are thought to play a
defining role in elicitation of immune responses, both in natural infection and in vaccination. We have developed an
Illumina MiSeq high-throughput sequencing protocol that allows determination of the human IgG subtype alongside
sequencing full-length antibody variable heavy chain regions. We thereby took advantage of the Illumina procedure
containing two additional short reads as identifiers. By performing paired-end sequencing of the variable regions and
customizing one of the identifier sequences to distinguish IgG subtypes, IgG transcripts with linked information of variable
regions and IgG subtype can be retrieved. We applied our new method to the analysis of the IgG variable region repertoire
from PBMC of an HIV-1 infected individual confirmed to have serum antibody reactivity to the Membrane Proximal External
Region (MPER) of gp41. We found that IgG3 subtype frequencies in the memory B cell compartment increased after halted
treatment and coincided with increased plasma antibody reactivity against the MPER domain. The sequencing strategy we
developed is not restricted to analysis of IgG. It can be adopted for any Ig subtyping and beyond that for any research
question where phasing of distant regions on the same amplicon is needed.
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Introduction
In the past decade, the development of high-throughput
sequencing technologies (Next Generation Sequencing, NGS)
has largely influenced research possibilities in immunology.
Sequencing of whole antibody repertoires has become feasible
and affordable, offering new approaches to quantitatively study
immune responses [1,2]. For example, the search for potent
neutralizing antibodies against human immunodeficiency virus
type 1 (HIV-1) and ways to elicit them by vaccination has in recent
years funneled extensive research that increasingly relies on NGS
of the IgG variable region, which enables high-resolution profiling
of antibody repertoires and the evolution of neutralizing antibodies
over time [3–8].
For immune effector functions, not only the variable part of an
antibody is important, but also the different isotypes of the
constant region. Antibodies of the same epitope specificity can
therefore elicit different effector functions depending on the
isotype. Antibody-dependent cell-mediated cytotoxicity (ADCC)
for instance is most active with isotype IgG1 followed by IgG3 and
IgA. Subtypes of IgG differentially protect mice from bacterial
infection [9] and are associated with chikungunya virus clearance
and long-term clinical protection [10]. An intriguing example of
the potential importance of IgG subtypes for immune reaction and
antibody elicitation is the membrane-proximal external region
(MPER) of gp41 of HIV-1. All of the broadly neutralizing anti-
MPER antibodies identified thus far, 4E10 and 2F5 [11] and the
recently identified 10E8 [12], were originally isolated as IgG3.
However, in the case of 4E10, the in vitro neutralization potency
is higher for IgG1 and absent for IgM [13]. It was suggested that
this is related to the longer hinge region and greater flexibility of
the IgG3 subtype [14,15]. Of note, in the recent RV144 trial [16],
the first phase III trial of an HIV-1 vaccine that reported some
efficacy, anti-gp120-specific isotype selection was skewed towards
IgG3 [17] and anti-HIV-1 IgG3 antibodies correlated with
antiviral function [18]. These examples highlight the importance
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of evaluating antibody specificity alongside subtype information
when studying immune responses and developing vaccines.
The Illumina MiSeq platform is rapidly becoming the dominant
sequencing system for antibody repertoires due to low error rates,
long read lengths, and declining costs [2]. State of the art
sequencing with Illumina technology currently allows for read
lengths of 26300 nucleotides on the widely used MiSeq platform.
This is sufficient to sequence an antibody variable region from
both ends with an overlap allowing combination of both reads to a
full-length variable region. However, the available read length
might not be enough for antibodies with a long heavy chain
complementary determining region 3 (HCDR3) to also include
determinants of the antibody subtype in the sequences, as they are
located too far downstream in the constant region. In order to
overcome this limitation, we use one of the indexing reads the
Illumina technology applies not in its intended function as a
sample identifier, but instead as a short extra read that identifies
the IgG subtype. This way, we can retrieve full-length variable
regions including the IgG subtype. Of note, in the same
sequencing runs light chains and other desired heavy chain
isotypes can be sequenced. The second Illumina index read is not
modified and used as designed to allow analysis of multiple
samples in a single run.
Methods
Primers
For the heavy chain, forward primers binding to the leader
sequences and reverse primers in the constant region were used
[6,19]. For the kappa light chain, primers binding in the leader
region [19] and in the constant region were used. Lambda light
chains were amplified with primers binding in the leader/variable
[19] and in the joining region [20]. Our customized protocol uses
sequencing adaptors and index sequences based on the Illumina
(San Diego, CA) TruSeq HT setup. Four random nucleotides were
inserted between the sequencing adaptor and the specific primer
to increase diversity and help cluster identification on the Illumina
MiSeq flow cell. The sequences of all primers are listed in Table 1.
Primers were ordered HPL-purified from Microsynth AG
(Balgach, Switzerland).
Clinical specimen
PBMC from healthy donors were purified from buffy coat
obtained from the Zurich Blood Transfusion Service (www.zhbsd.
ch). Cryopreserved PBMC from an HIV-1 infected individual,
patient ZA159, who developed strong MPER specific antibody
responses during disease progression (Liechti et al, in preparation),
were obtained through the Zurich primary HIV infection (ZPHI)
study [21]. BioSample accession numbers for the human subjects
are SAMN02911274 to SAMN02911277.
Ethics statement
Cryopreserved PBMC were obtained from an adult participant
enrolled in the Zurich Primary HIV-infection (ZPHI) study
(http://clinicaltrials.gov, ID 5 NCT00537966) [21]. The study
was approved by the ethics committee of the canton of Zurich and
written informed consent was obtained from all participating
individuals. Buffy coats from healthy donors were obtained from
the Zurich Blood Transfusion Service (www.zhbsd.ch) under a
protocol approved by the ethics committee of the canton of
Zurich.
PCR amplification
Total RNA was extracted from 10 * 106 PBMC (healthy donor)
or 2 * 106 PBMC (patient) using the RNeasy Mini Kit (Qiagen).
cDNA was synthesized in a total volume of 40 ul using 400 U
SuperscriptIII, 1 ug Oligo(dT)15 primer, 2 ul dNTP mix (10 mM
each nucleotide), 2 ul 0.1 M DTT and 1–10 ug RNA. Reverse
transcription was performed at 65uC for five minutes, 50uC for 60
minutes and 70uC for 15 minutes. cDNA was stored at 220uC. Ig
heavy, kappa and lambda genes were amplified in separate
reactions. All PCR reactions were performed in volumes of 50 ul
using 0.5 ul Phusion High-Fidelity DNA Polymerase (New
England Biolabs), 1 ul dNTPs (10 mM each nucleotide) and 5 ul
cDNA template. The first PCR reaction was performed with the
forward primer mix (0.05–0.15 uM each primer) and 0.5 uM gene
specific reverse primer. The temperature protocol was adapted
from [22] and consisted of once 98uC for 60 s; 4 cycles of 98uC
10 s, 45uC 30 s, 72uC 30 s; 4 cycles of 98uC 10 s, 50uC 30 s, 72uC
30 s; 17 cycles of 98uC 10 s, 68uC 30 s, 72uC 30 s; once 72uC
10 min.
The second PCR was performed with the forward index
adaptor primers (TS-D501 to TS-D508, depending on the number
of indices needed) and two custom reverse primers for either the
IgG heavy chains (TS7IgG(int)) or the light chains and heavy
chains of other isotypes (TS7icIgGcSeq). The temperature
protocol was once 98uC for 60 s; 4 cycles of 98uC 10 s, 55uC
30 s, 72uC 30 s; 4 cycles of 98uC 10 s, 60uC 30 s, 72uC 30 s; 17
cycles of 98uC 10 s, 72uC 30 s; once 72uC 10 min. The four
different healthy donor preparations differed in their amplification
strategies: prep 4 was amplified as described above, preps 1 and 2
were amplified with 1 ul cDNA template, prep 3 with 5 ul cDNA
template. Preps 1, 2 and 3 were then amplified for 12, 25 and 12
cycles in the second PCR, respectively. Samples from sorted cells
were amplified for 40 cycles in the first PCR.
The amplicons were purified using the QIAquick Gel Extrac-
tion Kit (Qiagen). Samples were quantitated using Quant-iT
PicoGreen (Invitrogen, Carlsbad, CA), normalized to a concen-
tration of 4 nM (based on an average length of about 525
nucleotides for light chains and 595 nucleotides for heavy chains)
and pooled equimolar for sequencing.
Sequencing strategy
In Illumina high-throughput sequencing technology, the DNA
insert to be sequenced is flanked on both sides by a primer binding
site, a short index and an adapter for binding to the flow cell.
Conventional use allows for paired-end sequencing (forward read
1 and reverse read 2) and dual multiplexing (index read 1 and
index read 2) by four independent sequencing reactions. On the
MiSeq system, custom primers for read 1, read 2 and for the index
read 1 can be used optionally. The priming of index read 2 cannot
be customized. Further, the number of cycles can be individually
chosen for all four reads, as long as the sum is not more than 25
cycles higher than the capacity of the kit used (available kits range
from 50–600 cycles). We used these features of the MiSeq system
to sequence the variable region of immunoglobulins in a paired-
end fashion, determined the subtype of IgGs via a 12 nucleotide
long identifier read and multiplexed samples by an 8 nucleotide
long index read (Figure 1).
The constant region of subtype IgG1 differs from IgG2/3/4 at
position 47 (AAG (K) vs. AGG (R), Figure 2). IgG1/3 and IgG2/4
differ at position 57 (TCT (S) vs. TCC (S)). By sequencing this
stretch of the constant region and defining the corresponding
sequences as indices, subtypes IgG1, 2/4 and 3 can be
differentiated. It is not possible to distinguish IgG2 and 4 at this
position; however, they can be separated based on the first triplet
IgG Sequencing with Subtype Information
PLOS ONE | www.plosone.org 2 November 2014 | Volume 9 | Issue 11 | e111726
Table 1. List of PCR and sequencing primers.
IGH forward Seq5N4-VH1LA CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGGACTGGACCTGGAGGAT
Seq5N4-VH1LB CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGGACTGGACCTGGAGCAT
Seq5N4-VH1LC CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGGACTGGACCTGGAGAAT
Seq5N4-VH1LD CTTTCCCTACACGACGCTCTTCCGATCTNNNNGGTTCCTCTTTGTGGTGGC
Seq5N4-VH1LE CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGGACTGGACCTGGAGGGT
Seq5N4-VH1LF CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGGACTGGATTTGGAGGAT
Seq5N4-VH1LG CTTTCCCTACACGACGCTCTTCCGATCTNNNNAGGTTCCTCTTTGTGGTGGCAG
Seq5N4-VH3LA CTTTCCCTACACGACGCTCTTCCGATCTNNNNTAAAAGGTGTCCAGTGT
Seq5N4-VH3LB CTTTCCCTACACGACGCTCTTCCGATCTNNNNTAAGAGGTGTCCAGTGT
Seq5N4-VH3LC CTTTCCCTACACGACGCTCTTCCGATCTNNNNTAGAAGGTGTCCAGTGT
Seq5N4-VH3LD CTTTCCCTACACGACGCTCTTCCGATCTNNNNGCTATTTTTAAAGGTGTCCAGTGT
Seq5N4-VH3LE CTTTCCCTACACGACGCTCTTCCGATCTNNNNTACAAGGTGTCCAGTGT
Seq5N4-VH3LF CTTTCCCTACACGACGCTCTTCCGATCTNNNNTTAAAGCTGTCCAGTGT
Seq5N4-VH4LA CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGAAACACCTGTGGTTCTTCC
Seq5N4-VH4LB CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGAAACACCTGTGGTTCTT
Seq5N4-VH4LC CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGAAGCACCTGTGGTTCTT
Seq5N4-VH4LD CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGAAACATCTGTGGTTCTT
Seq5N4-VH5LA CTTTCCCTACACGACGCTCTTCCGATCTNNNNTTCTCCAAGGAGTCTGT
Seq5N4-VH5LB CTTTCCCTACACGACGCTCTTCCGATCTNNNNCCTCCACAGTGAGAGTCTG
Seq5N4-VH6LA CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGTCTGTCTCCTTCCTCATC
Seq5N4-VH7LA CTTTCCCTACACGACGCTCTTCCGATCTNNNNGGCAGCAGCAACAGGTGCCCA
IGL forward Seq5N4-VL1 CTTTCCCTACACGACGCTCTTCCGATCTNNNNGGTCCTGGGCCCAGTCTGTGCTG
Seq5N4-VL2 CTTTCCCTACACGACGCTCTTCCGATCTNNNNGGTCCTGGGCCCAGTCTGCCCTG
Seq5N4-VL3 CTTTCCCTACACGACGCTCTTCCGATCTNNNNGCTCTGTGACCTCCTATGAGCTG
Seq5N4-VL45 CTTTCCCTACACGACGCTCTTCCGATCTNNNNGGTCTCTCTCSCAGCyTGTGCTG
Seq5N4-VL6 CTTTCCCTACACGACGCTCTTCCGATCTNNNNGTTCTTGGGCCAATTTTATGCTG
Seq5N4-VL7 CTTTCCCTACACGACGCTCTTCCGATCTNNNNGGTCCAATTCyCAGGCTGTGGTG
Seq5N4-VL8 CTTTCCCTACACGACGCTCTTCCGATCTNNNNGAGTGGATTCTCAGACTGTGGTG
IGK forward Seq5N4-VK12 CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGAGGSTCCCyGCTCAGCTGCTGG
Seq5N4-VK3 CTTTCCCTACACGACGCTCTTCCGATCTNNNNCTCTTCCTCCTGCTACTCTGGCTCCCAG
Seq5N4-VK4 CTTTCCCTACACGACGCTCTTCCGATCTNNNNATTTCTCTGTTGCTCTGGATCTCTG
IGG reverse TS7IgG(int) CAAGCAGAAGACGGCATACGAGATccGTTCGGGGAAGTAGTCCTTGAC
IGL reverse IgGcSeqhuVL1-rev GGGAAGACCGATGGGCCCTTGGTNNNNTAGGACGGTSASCTTGGTCC
IgGcSeqhuVL7-rev GGGAAGACCGATGGGCCCTTGGTNNNNGAGGACGGTCAGCTGGGTGC
IGK reverse IgGcSeqhuVKC-rev GGGAAGACCGATGGGCCCTTGGTNNNNAGATGGTGCAGCCACAGTTC
IGM reverse IgGcSeqhuIgM-rev GGGAAGACCGATGGGCCCTTGGTNNNNGGTTGGGGCGGATGCACTCC
IGA reverse IgGcSeqIgA-rev GGGAAGACCGATGGGCCCTTGGTNNNNTTGGGGCTGGTCGGGGATGC
indexing forward TS-D501 AATGATACGGCGACCACCGAGATCTACACTATAGCCTACACTCTTTCCCTA
CACGACGCTCTTCCGATCT
TS-D502 AATGATACGGCGACCACCGAGATCTACACATAGAGGCACACTCTTTCCCTA
CACGACGCTCTTCCGATCT
TS-D503 AATGATACGGCGACCACCGAGATCTACACCCTATCCTACACTCTTTCCCTA
CACGACGCTCTTCCGATCT
TS-D504 AATGATACGGCGACCACCGAGATCTACACGGCTCTGAACACTCTTTCCCTA
CACGACGCTCTTCCGATCT
TS-D505 AATGATACGGCGACCACCGAGATCTACACAGGCGAAGACACTCTTTCCCTA
CACGACGCTCTTCCGATCT
TS-D506 AATGATACGGCGACCACCGAGATCTACACTAATCTTAACACTCTTTCCCTA
CACGACGCTCTTCCGATCT
TS-D507 AATGATACGGCGACCACCGAGATCTACACCAGGACGTACACTCTTTCCCTA
CACGACGCTCTTCCGATCT
TS-D508 AATGATACGGCGACCACCGAGATCTACACGTACTGACACACTCTTTCCCTA
CACGACGCTCTTCCGATCT
IgG Sequencing with Subtype Information
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of the constant region (GCC (A) vs. GCT (A), Figure 2). This way,
all four IgG subtypes can be called unequivocally. To make
sequencing of light chains and heavy chain isotypes IgM and IgA
possible in the same run, the 59 end of the IgG constant region
(nucleotides 7–45) was added into the respective reverse primers so
that the same read 2 custom primer could be used for sequencing
of IgG, IgA, IgM and kappa (k) and lambda (l) light chains. A
separate index (klMA), which is complementary to the IgG1 index
to increase base variability during sequencing, was used for those
chains.
Illumina MiSeq sequencing
Pooled samples were denatured with NaOH according to the
protocol (Illumina), diluted with hybridization buffer HT1 to a
final dilution of 10 pM, spiked with 5% of PhiX control library
and loaded into a 500 cycle version 2 reagent cartridge. Custom
primers IgGcSeq and IgGcInd for the read 2 and the indexing
read, respectively, were diluted to 0.5 uM in hybridization buffer
HT1 and 600 ul loaded into well 19 (index read 1, IgGcInd) and
well 20 (read 2, IgGcSeq) of the reagent cartridge. The sample
sheet was adapted manually to allow any sequence (N12) as custom
index 1. Sequencing was performed for 2 * 250 cycles. The
workflow was set to ‘‘GenerateFASTQ’’. The raw sequencing data
have been uploaded to zenodo (doi:10.5281/zenodo.10863).
Data analysis
In order to obtain fastq files also for the index reads,
‘‘CreateFastqForIndexReads’’ in the MiSeqReporter.exe.config
file was set to 1 (true). Reads were first de-multiplexed by Illumina
MiSeq Reporter (version 2.4.60) based on index 2 that
distinguishes the different samples. Secondly, reads were assigned
to the different subtypes using a python script (available here
https://gist.github.com/ozagordi/11180835) as follows: IgG1,
IgG3 and light chains or heavy chains of other isotypes (klMA)
were identified by their index 1; IgG2 and IgG4 were additionally
discriminated based on the fourth nucleotide of the second read
(IgG2 if ‘G’, IgG4 if ‘A’, read 2 is reverse complementary). For the
IgG subtype indices a perfect match was required, for the klMA
klMA indexing
reverse
TS7icIgGcSeq CAAGCAGAAGACGGCATACGAGATTCTCCACGAGAAGGAGGAGGGTGCCA
GGGGGAAGACCGATGGGCCCTTGGT
custom sequencing IgGcSeq CCAGGGGGAAGACCGATGGGCCCTTGGT
IgGcInd CCATCGGTCTTCCCCCTGGCRCCCTSCTCC
doi:10.1371/journal.pone.0111726.t001
Table 1. Cont.
Figure 1. Amplification of Ig variable regions and high-throughput sequencing with subtype information. Antibody heavy and light
chain genes are shown schematically with leader regions in purple, variable (V-) regions in blue and constant (C-) regions in green. Ig heavy, kappa
and lambda light chain genes were amplified in separate reactions with family specific primers (represented by arrows) binding to leader and
constant region. Primer names are indicated exemplarily below the arrows and a complete list of all primers used can be found in Table 1.
Sequencing adaptors essential for the Illumina platform (flow cell binding sites P5 and P7, the index 2 region i5 and the read 1 sequencing primer
binding site Rd1 SP, illustrated in orange) were added by primer extension during a second PCR reaction, except for the IgG reverse primer
TS7IgG(int) which contained an adaptor and was used for both amplifications. Purified libraries were then sequenced using standard Illumina MiSeq
primers for read 1 and index 2, and customized primers for index 1 and read 2 (sequencing primers are shown in red and regions sequenced with red
dashed arrows).
doi:10.1371/journal.pone.0111726.g001
IgG Sequencing with Subtype Information
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index one mismatch was allowed. Reads not matching above
criteria were classified as undetermined. Forward and reverse
reads of a corresponding pair were stitched together using
PANDAseq [23] with a minimal overlap of 10 nucleotides and
analyzed by IMGT/HighV-QUEST [24]. Subtype frequencies
were calculated as the percentage of completely indexed and full-
length Ig variable region rearrangements.
Staining and cell sorting
Healthy donor PBMC were thawed, washed and split into four
samples. Staining for IgG subtypes was performed in PBS/1%
FCS at 4uC in the dark for 15 minutes using the following
antibodies and dyes: anti-CD19 V500 (BD Horizon), anti-CD3
APC-Cy7 (BioLegend), anti-CD14 APC-Cy7 (BioLegend), LIVE/
DEAD Near-IR Dead Cell Stain (Molecular Probes), anti-CD16
APC-Cy7 (BioLegend), anti-IgD PE-Cy5 (BioLegend, labeled in-
house) and either anti-IgG1 PE, anti-IgG2 PE, anti-IgG3 PE or
anti-IgG4 PE (all from SouthernBiotech). Cells were washed twice,
re-suspended in PBS/1% FCS and cells gated for CD3/14/16/
Dead- CD19+ IgD- and positive for one of the IgG subtypes were
sorted on a FACSAriaIII (Becton Dickinson). Sorted cells were
frozen at 280uC as dry pellets prior to analysis.
Results
Validation of high-throughput immunoglobulin variable
region sequencing with subtype identification
We developed a high-throughput method for the Illumina
MiSeq system to sequence the full variable region of immuno-
globulins in a paired-end fashion and identify at the same time the
subtype of IgGs via a 12 nucleotide long custom index read
(Figure 1). In order to test our sequencing strategy, we sequenced
IgG heavy and light chains from PBMC from a healthy donor and
an HIV-1 infected individual (ZA159 week 213, see below). The
healthy donor sample was amplified in four separate reactions
using different PCR conditions and cDNA input (see methods) to
confirm the robustness of the IgG subtype assignment. We focused
on assigning IgG subtypes and therefore did not sequence light
chains for preparations 1–3. Sequencing of the five samples
yielded a total of 10’249’237 passing filter reads.
19.3% (1’981’155) of the paired-end reads could not be
demultiplexed to one of the five samples and were categorized
as undetermined in regard of sample (Table 2). However, most of
these undetermined reads (193819101, 13.5% of total reads) had an
index identical to the TruSeq Universal primer and were
confirmed to be mostly PhiX control reads (data not shown).
The high number of undetermined reads therefore results from
high PhiX concentrations and not from problems associated with
sample preparation or library generation.
IgG subtype assignment based on index read 1 and the first
triplet of the constant region sequenced in read 2 resulted in 6
categories (IgG1, IgG2, IgG3, IgG4, klMA, undetermined reads)
for each sample (Table 2, column ‘‘Subtype assigned read pairs’’).
Of all read pairs demultiplexed to a sample, 97.5% (8’063’436)
were successfully assigned to one of the IgG subtypes or the light
chains.
To assemble full-length variable region sequences, correspond-
ing paired end reads were combined with PANDAseq [23]. The
overlap of reads peaked at about 100 nucleotides for heavy chains
and at about 100 and 150 nucleotides for kappa and lambda light
chains, respectively. 96.7% of all the read pairs overlapped
(Table 2, column ‘‘Sequences after PANDAseq’’). Sequences were
subjected to IMGT analysis. On average, 98% of both heavy and
Figure 2. Determinants of IgG subtype in the constant region. IgG1 to IgG4 CH1 regions were obtained from IMGT/GENE-DB [34]. Only the
first 107 nucleotides of the constant region are shown. Some alleles identical in this section have been omitted. Binding sites of the IgG reverse
primer (TS7IgG(int)) used for library preparation and the custom sequencing and indexing primers (IgGcSeq and IgGcInd, respectively) are
represented by dashed arrows on top. The full index 1 and the start of read 2 are indicated. Regions used for subtype assignment are shaded.
doi:10.1371/journal.pone.0111726.g002
IgG Sequencing with Subtype Information
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light chain sequences could be assigned to antibody variable
regions. The median heavy chain variable region length in our
dataset was approximately 360 nucleotides. In total, 796039242
subtype-assigned variable region sequences were obtained (Ta-
ble 2, column ‘‘Rearranged variable regions’’), showing that our
strategy efficiently sequences full-length variable regions with
linked subtype information.
The IgG subtype frequencies were found to be very consistent
among the four preparations of healthy donor and therefore
independent of PCR amplification strategies and cDNA input
(Table 2, Figure 3A, average frequency 6 std. deviation (%) for
IgG1 equals 56.160.2, IgG2 39.560.3, IgG3 4.060.1, IgG4
0.560.1). These values correspond well to IgG subtype frequen-
cies previously reported [25–27].
Validation of Ig subtype distribution analysis by NGS and
FACS sorting
To confirm the correct calling of the IgG subtype, PBMC of a
healthy donor were FACS sorted into the four different IgG
subtype populations. Purity after sorting was .99% for CD19+
IgG1, IgG2 and IgG3 positive cells (approximately 17000, 7000
and 4500 cells were sorted, respectively). IgG4 positive cells were
not further analyzed due to the low yield (total of 82 cells sorted)
and lack of possibility to assess post-sort purity by FACS. After
high-throughput sequencing of these populations in a separated
run and analysis by the same pipeline as described above, we
found subtype frequencies of 92.8% IgG1, 97.5% IgG2 and 98.7%
IgG3 for the IgG1, IgG2 and IgG3 sorted populations, respec-
Table 2. Read numbers and subtype frequencies.
Sample Subtype
Subtype assigned
read pairs
Sequences
after PANDAseq
Rearranged
variable regions
IgG subtypes
per sample
Healthy donor prep 1 IgG1 529’390 515’758 505’942 56.3%
IgG2 369’741 360’472 354’751 39.5%
IgG3 36’604 35’620 34’920 3.9%
IgG4 3’785 3’645 3’572 0.4%
klMA nd nd nd na
Undet(b) 11’577 na na na
Healthy donor prep 2 IgG1 692’673 674’590 660’899 55.9%
IgG2 488’483 475’851 467’958 39.6%
IgG3 50’454 48’880 47’773 4.0%
IgG4 6’191 5’968 5’859 0.5%
klMA nd nd nd na
Undet(b) 18’326 na na na
Healthy donor prep 3 IgG1 641’364 623’522 611’013 55.9%
IgG2 453’471 441’108 433’565 39.7%
IgG3 46’361 44’911 43’848 4.0%
IgG4 5’386 5’155 5’030 0.5%
klMA nd nd nd na
Undet(b) 18’149 na na na
Healthy donor prep 4 IgG1 699’378 679’819 665’267 56.3%
IgG2 481’592 468’433 460’214 39.0%
IgG3 52’028 50’328 49’024 4.2%
IgG4 7’199 6’900 6’695 0.6%
klMA 1’317’918 1’257’301 1’210’698 na
Undet(b) 84’941 na na na
ZA159 (week 213) IgG1 677’787 659’884 646’977 65.8%
IgG2 183’718 178’800 175’718 17.9%
IgG3 163’839 158’878 155’704 15.8%
IgG4 4’487 4’366 4’211 0.4%
klMA 1’151’587 1’097’762 1’053’604 na
Undet(b) 71’653 na na na
Undet (a) 1’981’155 na na na
Total reads 10’249’237 7’797’951 7’603’242
a) Undetermined in regard of sample.
b) Undetermined in regard of subtype.
nd =not done.
na = not applicable.
doi:10.1371/journal.pone.0111726.t002
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tively, highlighting the high specificity of our sequencing strategy
(Figure 3 BCD).
IgG subtype dynamics in an HIV-1 infected patient
To get an insight if our method is applicable to monitor IgG
subtype dynamics during infections, we selected an HIV-1 infected
patient with pronounced IgG3-mediated anti-MPER plasma
antibody response (Liechti et al. in preparation). Patient ZA159
was enrolled in the Zurich primary HIV infection study and has
been followed from the acute phase of HIV-1 infection onwards
[21]. The patient was on anti-retroviral treatment until week 92
post infection. Samples for NGS analysis were selected from three
time points with differential IgG3-mediated MPER plasma titers:
the first sample was taken 94 weeks post infection where no IgG3
MPER reactivity was apparent. Plasma from the second time
point, approximately 181 weeks post infection, showed interme-
diate IgG3 MPER reactivity and the third, approximately 213
weeks post infection, had highest IgG3 MPER reactivity.
In addition to the wk213 sample already sequenced in the first
run, frozen PBMC from the other two time points were sequenced
in a second run and 732’390 and 669’244 heavy chain reads were
obtained for those samples from week 94 and 181, respectively (see
Table S1 for reads statistics). Assigning these reads to the IgG
subtypes and comparing subtype frequencies to those from the
healthy donor showed higher IgG1 and decreased IgG2 frequen-
cies for the HIV-1 infected individual at all time points measured
(Figure 3A). Of note, during viral rebound after anti-retroviral
treatment cessation, IgG3 frequencies (measured by NGS) in the
memory B cell compartment increased markedly (Figure 3E),
which coincided with the increase in plasma IgG3 MPER
reactivity.
Discussion
Repertoire analysis of antibody variable genes by NGS has
become an important tool that allows unprecedented insight into
antibody development pathways and holds particular promise for
tailored vaccine design. Here, we describe a strategy for high-
throughput sequencing of antibody heavy chains including
determination of the IgG subtype. To achieve this, we adapted
the Illumina MiSeq standard protocol by employing a mixed
strategy of index reads and customized primers. Sequencing with
custom primers and indices has been done previously [28,29], but
to our knowledge our strategy of using an index read as a ‘‘third
read’’ is novel. Different samples can still be multiplexed in the
same run as the second index read remains available.
As we demonstrate here, our method determines IgG subtypes
very reliably. We could successfully assign 97.5% of the reads in
the demultiplexed samples to a subtype, although our identifier is
12 nucleotides long and the assignment criteria have to be very
strict. Consistently, over 96% of both heavy and light chain
sequences could be assigned to rearranged variable regions,
demonstrating that our sequences are full-length antibody variable
regions.
As the Hamming distances between the subtype identifiers are
only single nucleotides, we do not allow mismatches in the subtype
indices, except one mismatch in calling the klMA category. There
remains a risk of misidentification of the subtype by a PCR or
sequencing error, artifact recombination [30] or a mutation in the
constant region. If further exclusion of misidentification by
sequencing errors in the indices should become warranted for
specific research questions, our analysis could be adapted to first
collapse identical variable regions and then use the consensus of
their index reads to determine the subtype. While this approach
would decrease potential misidentifications, a full repertoire
analysis of the variable domains would be required. Although this
was beyond the scope of our current study, we consider this a
useful and valuable modification of our analysis for future projects.
Yet, despite the increased accuracy of this approach, pre-existing
mutations in the constant region will not be detected and
dismissed. Another possibility to empower subtype identification
would be full-length sequencing of the CH1, as the difference
between subtypes over the whole CH1 would increase to 6–15
nucleotides. However, the required read lengths are currently
limiting for Illumina technology, as additional sequencing of the
CH1 domain further downstream of our index would be necessary
[27]. Even if this became possible, splitting up the available read
length in several smaller reads might still be preferable, as per base
sequencing quality decreases with increasing read length.
Figure 3. IgG subtypes are reliably identified. A) IgG subtype
frequencies of four preparations of PBMC from one healthy donor were
determined by sequencing. Different PCR protocols (prep 1 to prep 4)
as described in the methods section have been applied to amplify
antibody transcripts. Read numbers for the different preparations are
listed in Table 2. B–D) PBMC of a healthy control were sorted by FACS
into individual IgG subtype populations and sequenced. 292219006,
290449153 and 198899353 reads were obtained for sorted IgG1 positive
cells (B), IgG2 positive cells (C) and IgG3 positive cells (D), respectively,
and assigned to the IgG subtypes. E) IgG subtype frequencies of time
points week 94, week 181 and week 213 (Table 2, Table S1) for patient
ZA159. The average frequencies from the healthy control preparations
1–4 are shown as a comparison. Subtype frequencies in all panels were
calculated as the percentage of all completely indexed and full-length
variable region rearrangements.
doi:10.1371/journal.pone.0111726.g003
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Although the purity of sorted subtype populations was higher
measured by FACS than the IgG subtype frequency in the sorted
samples determined by our sequencing approach, we argue that
the sequencing approach serves as a quality control for the sorting
and not the other way round, as even in the most controlled set up,
FACS sorting will suffer from residual cross-reactivity from the
staining antibodies.
No bias or cross-reactivity is expected in sequencing as this
method is independent of immunoglobulin surface expression and,
importantly, all subtypes are amplified with the same primer. A
common primer is a key advantage compared to individual
primers for each subtype. It is, however, important to note that our
method, as it is presented here, is only semi-quantitative as we
focused solely on subclass determination. If needed, a quantitative
analysis would require a full repertoire analysis to avoid counting
the same variable region multiple times. Since oversampling
should be proportional for all the subtypes, distribution of subtype
frequencies as shown here should not be affected.
Our method has the potential of widespread application and
particularly in the antibody field the chance to fill a gap in
information. So far, antibody subtypes have either only been
determined in bulk in plasma samples where the information could
not be linked to variable region sequences, or on the level of
antibodies cloned out of single cells, where the potential for high-
throughput applications is limited.
As recent data have highlighted, information on IgG subtype
profiles could be very useful to study elicitation and dynamics of
IgG antibodies of different subtypes, and could provide informa-
tion on the quality of infection- and vaccine-induced B cell
responses [18,31,32].
Our method can easily be adapted for IgA subtype discrimi-
nation. It can also be applied in other cases where priming of three
reads is necessary or sequence information of a distant site is
needed, e.g. in haplotype analysis used in genetics. Overall, our
method combines the strength of antibody repertoire analyses by
NGS with subtype information of the obtained sequences,
enabling in-depth analysis of immune responses following infec-
tions or vaccinations.
Supporting Information
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